Revenue Breakdown
Composition ()
No data
Revenue Streams
Abbott Laboratories (ABT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diabetes Care, accounting for 17.8% of total sales, equivalent to $1.98B. Other significant revenue streams include Core Laboratory and Adult Nutritionals. Understanding this composition is critical for investors evaluating how ABT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Abbott Laboratories maintains a gross margin of 53.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 20.34%, while the net margin is 15.50%. These profitability ratios, combined with a Return on Equity (ROE) of 13.07%, provide a clear picture of how effectively ABT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ABT competes directly with industry leaders such as TMO and ISRG. With a market capitalization of $202.18B, it holds a leading position in the sector. When comparing efficiency, ABT's gross margin of 53.44% stands against TMO's 41.02% and ISRG's 66.44%. Such benchmarking helps identify whether Abbott Laboratories is trading at a premium or discount relative to its financial performance.
